Rituximab immunotherapy: it’s getting personal

In this issue of Blood , Tout and colleagues add another layer of personalization to rituximab therapy in patients with diffuse large B-cell lymphoma (DLBCL) by demonstrating the relationship between baseline total metabolic tumor volume (TMTV 0 ), rituximab exposure, and outcomes from therapy. 1